Neha Krishnamohan net worth and biography

Neha Krishnamohan Biography and Net Worth

Neha Krishnamohan joined our board of directors in September 2022. Ms Krishnamohan is currently the chief financial officer and executive vice president of corporate development at Artiva Biotherapeutics, with over 15 years of experience in healthcare investment banking, financial and strategic leadership. She was most recently the Chief Financial Officer and Executive Vice President, Corporate Development at Kinnate Biopharma Inc., a clinical stage precision oncology company where she led the company’s financial operations, business development, and investor relations / communications functions. Ms Krishnamohan was also a leader on Kinnate’s exploration of strategic alternatives, which resulted in a successful asset sale to Pierre Fabre Laboratories and the sale of Kinnate to XOMA Corporation. Prior to Kinnate, Ms Krishnamohan was a vice president in the Healthcare Investment Banking Group and a member of the Mergers and Acquisitions (M&A) Group within the Investment Banking Division at Goldman Sachs. While at Goldman Sachs, she established herself as a senior leader in the healthcare coverage group, working with a variety of biopharmaceutical boards and management teams on a broad range of strategic financial matters, executing financings as well as leading M&A transactions. Of note, she was one of the lead bankers on Arcutis’ highly successful 2020 initial public offering. Ms Krishnamohan has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors. Ms Krishnamohan holds a BSE with a double major in Biomedical Engineering and Economics from Duke University.

What is Neha Krishnamohan's net worth?: The estimated net worth of Neha Krishnamohan is at least $690.24 thousand as of November 13th, 2025. Ms. Krishnamohan owns 22,123 shares of Arcutis Biotherapeutics stock worth more than $690,238 as of December 8th. This net worth estimate does not reflect any other assets that Ms. Krishnamohan may own. Learn More about Neha Krishnamohan's net worth.
How do I contact Neha Krishnamohan?: The corporate mailing address for Ms. Krishnamohan and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Neha Krishnamohan's contact information.
Has Neha Krishnamohan been buying or selling shares of Arcutis Biotherapeutics?: During the last ninety days, Neha Krishnamohan has sold $939,692.80 in Arcutis Biotherapeutics stock. Most recently, Neha Krishnamohan sold 40,504 shares of the business's stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $23.20, for a transaction totalling $939,692.80. Following the completion of the sale, the director now directly owns 22,123 shares of the company's stock, valued at $513,253.60. Learn More on Neha Krishnamohan's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Patrick Heron (Director), Neha Krishnamohan (Director), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Latha Vairavan (CFO), Todd Watanabe (Insider), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 4 times. They purchased a total of 7,434 shares worth more than $99,276.66. During the last year, insiders at the sold shares 50 times. They sold a total of 552,442 shares worth more than $11,637,612.79. The most recent insider tranaction occured on December, 1st when insider Masaru Matsuda sold 1,657 shares worth more than $50,091.11. Insiders at Arcutis Biotherapeutics own 9.4% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 12/1/2025.

Neha Krishnamohan Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/13/2025	Sell	40,504	$23.20	$939,692.80	22,123

Neha Krishnamohan Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $31.20

$30.39

$31.45

50 Day Range

MA: $24.25

$18.62

$31.20

2 Week Range

Now: $31.20

$11.13

$31.45

Volume

1,284,715 shs

Average Volume

2,309,840 shs

Market Capitalization

$3.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69